MarketPulse

blood-brain barrier

2 articles
The Motley FoolThe Motley Fool··Sara Appino

Privium Fund Bets $5M on Denali Ahead of FDA Approval Win

Privium Fund Management acquires $5.07M stake in Denali Therapeutics following FDA approval of first commercial drug Avlayah for Hunter syndrome treatment.
DNLIclinical trialsneurodegenerative diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arvinas to Showcase ARV-102 Parkinson's Data at Major Neurology Conference

Arvinas will present Phase 1 data for ARV-102, a PROTAC LRRK2 degrader, at AD/PD 2026 conference in Copenhagen, with Phase 1b trial planned for progressive supranuclear palsy.
ARVNPhase 1 clinical trialParkinson's disease